Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.

Author: CryerByron, DrossmanDouglas A, Losch-BeridonTaryn, MareyaShadreck M, Mazen JamalM, SpieringsEgilius L H, WangMartin

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Oral lubiprostone was effective in relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain. Methadone use was associated with a lower response to lubiprostone treatment.
Paper Details　
Original Abstract of the Article :
The efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation (OIC) in patients with chronic noncancer pain were evaluated in a randomized, double-blind, placebo-controlled study. These data were also pooled with those from two similar phase 3 studies to explore ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/pm/pnx156

データ提供：米国国立医学図書館（NLM）

Lubiprostone: A Light in the Darkness of Opioid-Induced Constipation

This study focuses on the perplexing issue of opioid-induced constipation (OIC), a common side effect of opioid medications. Imagine a camel struggling to move through a patch of thick sand, unable to find its usual rhythm. The research investigates the efficacy and safety of oral lubiprostone in alleviating symptoms of OIC in patients with chronic noncancer pain. The authors conducted a randomized, double-blind, placebo-controlled trial to assess the effects of lubiprostone, pooling these data with two similar phase 3 studies to examine the impact of methadone on treatment outcomes.

A Ray of Hope: Lubiprostone for Opioid-Induced Constipation

The study revealed that oral lubiprostone effectively relieved symptoms of OIC in patients with chronic noncancer pain. The results suggest that lubiprostone offers a promising treatment option for individuals struggling with this common side effect of opioid therapy. The research also explored the influence of methadone on treatment response, providing valuable insights for clinicians managing patients with OIC who are also on methadone.

Managing Opioid Side Effects: A Holistic Approach

This research emphasizes the importance of addressing the side effects of opioid medications. Lubiprostone offers a potential solution for OIC, improving patient comfort and quality of life. The study also highlights the need for a comprehensive approach to opioid management, taking into account the potential for drug interactions and individualized patient needs.

Dr. Camel's Conclusion

Lubiprostone offers a glimmer of hope in the arid landscape of opioid-induced constipation. This research highlights the efficacy and safety of lubiprostone as a potential treatment option for this common side effect, emphasizing the importance of a holistic approach to managing opioid therapy.

Date :
  1. Date Completed 2019-07-01
  2. Date Revised 2019-07-01
Further Info :

Pubmed ID

29016868

DOI: Digital Object Identifier

10.1093/pm/pnx156

Related Literature

Article Analysis
・Effects of lubiprostone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.